News

Pfizer recently dosed a first patient in the Phase 1 clinical study of PF-06671008, which targets P-cadherin and CD3. Increased levels of the protein P-cadherin have been reported

EGFR is an important molecular target for drug treatment; however, the lack of relevant experimental models bearing non-canonical EGFR mutations (such as exon 20 insertions) has been a

The regulator confirmed that the proposed comparator is acceptable and the trial design would meet the requirements established in its guidance for ABSSSI studies. In addition, the FDA

New Leaf Venture Partners led the financing, which included new investors Frazier Healthcare Partners, Longitude Capital, and Osage University Partners. Existing investors Adams Street Partners, LVP Life Science

DRM01 is a novel, small molecule designed to inhibit sebum production after topical application to treat acne. It is designed to target acetyl coenzyme-A carboxylase, an enzyme that

The Phase 1 portion of the study will test the safety and tolerability of escalating doses of X4P-001 in combination with Inlyta (axitinib), a kinase inhibitor approved for

The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second

WAVE’s DMD program is based on preclinical data demonstrating an approximate 25-fold improvement in exon-skipping efficiency compared to drisapersen and eteplirsen, suggesting the potential for improved potency and

Taiho Ventures will be investing globally in the start-up companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit